A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
146actual
Sites
42
Countries
Canada, Italy, Spain +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-07-20 | actual | When the study began enrolling |
| Primary completion | 2025-10-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-21 | actual | The whole study's end, after follow-up |
| First posted | 2023-07-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Overweight or Obesity
- CKD
- Type 2 Diabetes
Interventions
- Drug: Retatrutide — also filed as LY3437943
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from Baseline in Glomerular Filtration Rate (mGFR)
measured Baseline, Week 24
Publications
- PMID 41160422 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed